Zymogenetics, Inc.

Systimmune, Inc.

Baili-bio (chengdu) Pharmaceutical Co., Ltd.

Other

Bristol-myers Squibb Compnay

Sichuan Baili Pharmaceutical Co. Ltd.

Baili-bio Pharmaceutical Co., Ltd.

Zeren Gao

Scott R Presnell

Brian Robert Kovacevich

Blair R Renshaw

Yi Zhu

Paul O Sheppard

Dong Xia

Charles E Hart

Steven D Levin

Theodore E Whitmore

Christopher S Piddington

James William West

Cindy A Sprecher

Darrell C Conklin

Joseph Leon Kuijper

Ole Olsen

Kimberly E Shoemaker

Phil Tan

David Jellyman

Bill Brady

Mark F Maurer

Stephen R Jaspers

Debra G Gilbertson

Cameron Brandt

Janine M Bilsborough

Mark W Rixon

Rolf E Kuestner

Katrina Bykova

Jeffrey B Adamo

Yu Liang

Anne-Marie K Rousseau

Brian A Fox

Wenfeng Xu

Andrew Lawrence Feldhaus

Eugene C Yi

Jacob J Kennedy

Donald C Foster

Pallavur V Sivakumar

Eric Chadwick

Shi Zhuo

Lan Chen

Anne E Jensen

Jonathan K Fallen

Gayle Yamamoto

Camilla Wang

Cameron S Brandt

Julia E Novak

Jane A Gross

Stacey R Dillon

Angela K Hammond

Francis J Grant

James L Holloway

Maria M Dasovich

Steven K Burkhead

Hui Huang

Frederick J Ramsdell

Kimberty E Shoemaker

Nga Sze Amanda Mak

Nge Sze Amanda Mak

Edward D Howard

Eric M Chadwick

Nga Sze Mak

A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different members of EGFR family.

Bispecific tetravalent antibodies and methods of making and using thereof

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.

Guidance and navigation control proteins and method of making and using thereof

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).

Guidance and Navigation Control proteins and method of making and using thereof

The application provides anti-4-1BB monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Anti-4-1BB antibodies and methods of making and using thereof

The disclosure provides a tetra-specific antibody monomer having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, a second scFv domain, and a third scFv at the C-terminal, wherein the first scFv domain, the Fab domain, the second scFv domain, and the third scFv domain each has a binding specificity against a different antigen. In one embodiment, the antigen is a tumor antigen, an immune signaling antigen, or a combination thereof. Multi-specific antibodies comprising the disclosed tetra-specific antibodies are also provided.

Multi-specific antibodies and methods of making and using thereof

The application provides tri-specific antibody monomers having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first scFv domain at the N-terminal, a Fab domain, a Fc domain, and a second scFv domain at the C-terminal. In one embodiment, the first scFv domain, the Fab domain, and the second scFv domain each has a binding specificity against a different antigen.

Tri-specific antibodies

The application provides the anti-PD-L1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Anti-PD-L1 antibodies and methods of making and using thereof

The applications provides the anti-CD3 monoclonal antibodies, antigen-binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to active CD3+ T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Anti-CD3 antibodies and methods of making and using thereof

The application provides anti-ROR1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Anti-ROR1 antibodies and methods of making and using thereof

The application provides anti-PD-1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.

Anti-PD-1 antibodies and methods of making and using thereof

A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different epitopes on HER2 receptor.

Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

B7 family member zB7H6 and related compositions and methods

The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.

Method of treating CD155 expressing cancers

Screening method for inhibitors of binding of zBR7R1 to CD155

Growing community of inventors

Redmond, WA, United States of America

Zeren Gao